Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients.
Zhanwei Du +8 more
doaj +1 more source
Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis
Introduction: Paxlovid (nirmatrelvir/ritonavir) is a new oral antiviral drug that is used for coronavirus disease 2019 (COVID-19) and is administered to patients with mild to moderate disease for five consecutive days.
Yu Wang +5 more
doaj +1 more source
Paxlovid Awareness, Reporting Bias. [PDF]
Widera, Eric, Lee, Todd C, Prasad, Vinay
openaire +4 more sources
Québec authorizes pharmacists to prescribe Paxlovid
openaire +2 more sources
Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol. [PDF]
Bactawar SB, Gaibor C, Abdul-Waheed M.
europepmc +1 more source
Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics. [PDF]
Zhu X +8 more
europepmc +1 more source
Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
Philipponnet, Carole +4 more
openaire +2 more sources
Cardiovascular Outcomes in COVID-19 Patients Treated with Paxlovid: A Multicenter Retrospective Study. [PDF]
Chen WL +10 more
europepmc +1 more source
Safety and efficacy of major antiviral and immune therapies in pregnancy for maternal viral infections: evidence synthesis of maternal and neonatal outcomes. [PDF]
Sleman S +4 more
europepmc +1 more source
Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report. [PDF]
Yu W +6 more
europepmc +1 more source

